Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, has announced the pricing of its underwritten public offering of 9,433,963 shares of its common stock at a price to the public of US$13.25 per share and the pricing of US$200 million aggregate principal amount of its 5% convertible senior notes due 2027. The aggregate gross proceeds to Gossamer from the offerings, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately US$325 million. The offerings are expected to close on May 21, 2020, subject to customary closing conditions.
Latham & Watkins LLP represented Gossamer Bio in the offerings with a corporate team led by San Diego partner Matt Bush and New York partner Greg Rodgers, with counsel Kevin Reyes and associates Andrew Blumenthal, Briana Cornelius, Alisa Lalana, and Jessi Lim. Advice was also provided on tax matters by New York partner Elena Romanova, with associate Michael Yu.